PHP
AMRX icon

Parkman Healthcare Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Parkman Healthcare Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.74M Buy
+300,752
New +$4.04M 0.39% 69

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Parkman Healthcare Partners's AMRX Position: Q1 2026 in Review

Parkman Healthcare Partners opened a new position in Amneal Pharmaceuticals (AMRX) in Q1 2026: 300,752 shares worth $3.74M. The stake represents 0.39% of the portfolio and ranks #69 among its holdings.

315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Parkman Healthcare Partners held 300,752 shares of Amneal Pharmaceuticals worth $3.74M as of Q1 2026.
  • Amneal Pharmaceuticals was a new Parkman Healthcare Partners position in Q1 2026.
  • Amneal Pharmaceuticals made up 0.39% of Parkman Healthcare Partners's portfolio in Q1 2026, its #69 holding.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.